Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
Researchers must adhere to all institutional, national, and international guidelines for animal welfare and human subject research if applicable
Animal studies in pigs at doses up to 1.1 mg/kg showed no adverse effects
The American Journal of Medicine, 124 (1), 85.e1-85.e8
In such cases, a non-surgical mild procedure like microdermabrasion, micro laser peel, or any other type of laser may achieve the goal
US$ 21.37
US$ 22.32
US$ 29.92
US$ 23.78
US$ 29.23
US$ 24.32
US$ 29.29
US$ 26.76
US$ 20.96
